BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 15238825)

  • 1. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
    Kural BV; Orem C; Uydu HA; Alver A; Orem A
    Coron Artery Dis; 2004 Aug; 15(5):277-83. PubMed ID: 15238825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.
    Orem C; Orem A; Uydu HA; Celik S; Erdöl C; Kural BV
    Coron Artery Dis; 2002 Feb; 13(1):65-71. PubMed ID: 11917201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage.
    Harangi M; Seres I; Varga Z; Emri G; Szilvássy Z; Paragh G; Remenyik E
    Eur J Clin Pharmacol; 2004 Dec; 60(10):685-91. PubMed ID: 15490140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
    Paragh G; Törocsik D; Seres I; Harangi M; Illyés L; Balogh Z; Kovács P
    Curr Med Res Opin; 2004 Aug; 20(8):1321-7. PubMed ID: 15324535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
    Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
    J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC; Van Tol A; Dallinga-Thie GM; Liem A; Dunselman PH; Van der Bom JG; Jukema JW
    Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
    Castaño G; Mas R; Fernández L; Illnait J; Mesa M; Alvarez E; Lezcay M
    Drugs Aging; 2003; 20(2):153-63. PubMed ID: 12534315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease.
    Orem A; Yandi YE; Vanizor B; Cimşit G; Uydu HA; Malkoç M
    Clin Biochem; 2002 May; 35(3):217-24. PubMed ID: 12074830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
    Thallinger C; Urbauer E; Lackner E; Graselli U; Kostner K; Wolzt M; Joukhadar C
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):551-7. PubMed ID: 16372516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
    J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
    Romero R; Calviño J; Rodriguez J; Sánchez-Guisande D
    Nephrol Dial Transplant; 2000 Sep; 15(9):1446-9. PubMed ID: 10978406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
    Navarro JF; Mora C; Muros M; García-Idoate G
    Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.
    Branchi A; Fiorenza AM; Torri A; Muzio F; Berra C; Colombo E; Dalla Valle E; Rovellini A; Sommariva D
    Clin Ther; 2001 Jun; 23(6):851-7. PubMed ID: 11440285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.